Tagged with car-t

Global One of the enduring conundrums around ground-breaking and potentially paradigm-shifting treatments such as CAR-T is the ever-thorny question of how fast to move them to market when the promise seems so great, but the evidence remains so patchy.   So far, top tier regulators such as the US FDA and…

Global Chimeric antigen receptor (CAR-T) therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among patients about its potential as a revolutionary, perhaps even decisive, new pillar in the war on cancer. Five years later, however, many are still left…

Global In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are seeking to become much more than just purveyors of pills and expand along the life science continuum, providing positive healthcare…

Global Marc Boutin, Novartis’ global head of patient engagement, outlines the company’s “bold vision” of patient engagement and the actions that need to be taken for CAR-T patients in the immediate, short- medium-, and long-term. This piece forms part of our special section, InFocus: Patient Engagaement in the Era of CAR-T.…

Europe Building on points developed in his 2020 PharmaBoardroom interview, Professor Nicolaus Kröger of the European Society for Blood and Marrow Transplantation (EBMT) outlines the progress made by the multi-stakeholder GoCART Coalition towards greater harmonisation of cell and gene therapy research in Europe, the challenges of integrating patient-reported outcomes into its…

InFocus BACK TO HOME     Patient Engagement in the Era of CAR-T   BACK TO HOME Patient Engagement Roundtable: A Varied Global Picture As complex cutting-edge therapies come online, industry sponsors are increasingly looking to engage with patients, caregivers, and advocacy groups earlier and more broadly in the drug development…

InFocus BACK TO HOME     Patient Engagement in the Era of CAR-T   BACK TO HOME CGT, Real World Evidence & The Patient Experience One of the enduring conundrums around ground-breaking and potentially paradigm-shifting treatments such as CAR-T is the ever-thorny question of how fast to move them to market…

InFocus BACK TO HOME     Patient Engagement in the Era of CAR-T   BACK TO HOME CAR-T and the Art of Managing Expectations Chimeric antigen receptor (CAR-T) therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among patients about…

InFocus BACK TO HOME     Patient Engagement in the Era of CAR-T   BACK TO HOME Rendering CGT Genuinely Patient Centric In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers…

InFocus BACK TO HOME Patient Engagement in the Era of CAR-T BACK TO HOME Marc Boutin Global Head of Patient Engagement, novartis SHARE Share on twitter Share on linkedin “How are you today?” For patients, this question may be a challenge. Honest answers can stop a conversation straight away. I know…

Germany Christian Conrad outlines his role as patient engagement lead for Novartis Oncology in Germany, how individual patient interactions differ from those with advocacy groups, and the current situation for cancer patients eligible to receive Novartis’ CAR-T therapy in Germany.   There has been a big change in the last few…

USA Melanie Croce-Galis, RN, MPH explains the specificities of her work as patient engagement lead for Novartis Oncology in the US market, where significant disparities in patient access to information and to care throw up several challenges. Croce-Galis also outlines the work being done around CAR-T therapies and why integrating and…